Dr. Yang-Xin Fu obtained medical degree in Shanghai Medical University (1983) and PhD in University of Miami (1990). His resident training was completed in Washington University (1994). He had become an attending physician and immunologist in the University of Chicago since 1998. He was awarded an established investigator for cancer research in Texas and move to UT Southwestern Medical Center (2015). His team has been exploring new mechanisms for cancer therapies related innate sensing. His team has explored novel mechanisms of adaptive immunity that is triggered by various radiation, chemotherapies, and targeted. His team has explored new mechanisms for tumor targeting oractivating antibodies and cytokinesto re-activate immunity inside tumor. His work has been highly cited more than 41,000(h index: 103).
This is a million dollar question. There are many new targets but few have demonstrated their potency as single treatment in manyclinical trials. It is unclear why. Some showed potential drug candidate, such as LAG-3 while other might if they can be modified to reduce toxicities such asanti-CD40, anti-CD47/SIRP, anti-CD137, and anti-Tim3. Cytokines will be next wave since their potency is clear but too toxic at therapeutic window. That could be improved as next generation of cytokines is moving to right direction.
When combination with anti-CD20. But few have shown its potency in solid tumor. In addition to RBC, almost all cells have CD47. Some studied focus onantibodies that have diminished binding to RBC, what about other cells. It isimportant to allow anti-CD47 reaches to tumor cells. Another way is to use anti-CD47 on immunecells, especially suppressive immune cells, such as Treg. I will discuss more in this meeting.
It appears that targeting on tumor antigens is challenging as most tumor antigens are not specific to tumors. Some are more specific but very low expression on tumor cells. Therefore, it is hard to bring other partners into tumor microenvironment. We need more specific and highly expressed molecules on tumorcells. We will talk about this issue in the meeting.
近期，您在Journal of Experimental Medicine发表了一项研究，揭示了肠道微生物中的特定成员双歧杆菌有望通过在肿瘤中定植增强抗CD47疗法的抗肿瘤疗效。肿瘤免疫与肠道微生物疗法联合在美国的转化和开发趋势如何？您认为将给中国带来哪些启示？
When we tried to convince the reviewers that tumor tissues are good environment to host gut microbiota and gut microbiota might contribute to immune responses against tumor. But the reviewers were not convinced for human tumors until more recent studies showed that they are detected in many humantumors that are not gut associated origins. It is still challenging to deliver enough gut microbiota into tumor tissues effectively to synergize with immunotherapy. On the other hand, it is hard to evaluatetheir toxicity.